Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Intec Pharma Ltd. (NASDAQ:NTEC) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical Inc.	51.49M	80.79	197.61M	-3.90	0.00
Intec Pharma Ltd.	N/A	0.00	43.54M	-1.40	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Ultragenyx Pharmaceutical Inc. and Intec Pharma Ltd.

	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical Inc.	-383.78%	-29.3%	-25.4%
Intec Pharma Ltd.	0.00%	0%	0%

Analyst Ratings

The table delivered features the ratings and recommendations for Ultragenyx Pharmaceutical Inc. and Intec Pharma Ltd.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Ultragenyx Pharmaceutical Inc.	0	3	7	2.70
Intec Pharma Ltd.	0	0	0	0.00

The average target price of Ultragenyx Pharmaceutical Inc. is $72, with potential downside of -1.15%.

Insider & Institutional Ownership

Ultragenyx Pharmaceutical Inc. and Intec Pharma Ltd. has shares held by institutional investors as follows: 0% and 39.64%. Insiders held 0.4% of Ultragenyx Pharmaceutical Inc. shares. Competitively, Intec Pharma Ltd. has 11.81% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Ultragenyx Pharmaceutical Inc.	4.21%	33.9%	19.9%	-21.29%	36.36%	51.89%
Intec Pharma Ltd.	-5.95%	4.85%	37.69%	116.32%	34.75%	9.02%

For the past year Ultragenyx Pharmaceutical Inc. was more bullish than Intec Pharma Ltd.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.